Ryan J. Watts - 03 Jan 2022 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role: President and CEO, Director
Signature: /s/ Tyler Nielsen, by power of attorney
Issuer symbol: DNLI
Transactions as of: 03 Jan 2022
Transactions value $: $0
Form type: 4
Filing time: 05 Jan 2022, 18:03:31 UTC
Previous filing: 03 Dec 2021
Next filing: 07 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNLI	Common Stock	Award	$0	+62,000	+41%	$0	213,691	03 Jan 2022	Direct	F1, F2
holding	DNLI	Common Stock						2,103,368	03 Jan 2022	See footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNLI	Stock Option (right to buy)	Award	$0	+186,500		$0	186,500	03 Jan 2022	Common Stock	186,500	$47.27	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2023 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
F2	Includes 213,691 restricted stock units.
F3	The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
F4	25% of the shares subject to the option shall vest on January 3, 2023, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.